These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33276720)

  • 1. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.
    Wang P; Qiao H; Wang R; Hou R; Guo J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):510. PubMed ID: 33276720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of anemia on in-stent restenosis after percutaneous coronary intervention.
    Hu H; Wang S; Tang G; Zhai C; Shen L
    BMC Cardiovasc Disord; 2021 Nov; 21(1):548. PubMed ID: 34798833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visit-to-visit HbA
    Yang CD; Shen Y; Lu L; Yang ZK; Hu J; Zhang RY; Shen WF; Ding FH; Wang XQ
    Cardiovasc Diabetol; 2020 Sep; 19(1):133. PubMed ID: 32887588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.
    Qin Z; Zhou K; Li YP; Wang JL; Cheng WJ; Hu CP; Shi C; He H; Zhou YJ
    Cardiovasc Diabetol; 2019 Jan; 18(1):11. PubMed ID: 30691501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis.
    Tocci G; Barbato E; Coluccia R; Modestino A; Pagliaro B; Mastromarino V; Giovannelli F; Berni A; Volpe M
    Am J Hypertens; 2016 Apr; 29(4):509-18. PubMed ID: 26271109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.
    Li M; Hou J; Gu X; Weng R; Zhong Z; Liu S
    Eur J Med Res; 2022 Jan; 27(1):12. PubMed ID: 35065663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.
    Cheng G; Chang FJ; Wang Y; You PH; Chen HC; Han WQ; Wang JW; Zhong NE; Min ZQ
    Med Sci Monit; 2019 Jan; 25():240-247. PubMed ID: 30617247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
    He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
    BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Fasting Hypertriglyceridemia as an Independent Risk Factor for Coronary In-Stent Restenosis after Primary Bare Metal Stent Implantation in Patients with Coronary Artery Disease.
    Yoshimura M; Umemoto S; Kawano R; Hiromoto M; Yamada M; Fujimura T; Tanaka M; Nao T; Miura T; Yano M
    Int Heart J; 2021; 62(5):970-979. PubMed ID: 34588411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
    Zhu Y; Liu K; Chen M; Liu Y; Gao A; Hu C; Li H; Zhu H; Han H; Zhang J; Zhao Y
    Cardiovasc Diabetol; 2021 Jul; 20(1):137. PubMed ID: 34238294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.